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ABSTRACT 
 Retinopathy of prematurity (ROP) is a major cause of blindness among premature, low 
birth weight infants as a result of pathological angiogenesis. Angiogenesis, the growth of new 
blood vessels from preexisting vessels, occurs in the veins and capillaries of the body. The 
process is highly regulated during early development and maturation. However, under abnormal 
conditions such as a decrease in oxygen levels or hypoxia, angiogenesis can become 
dysregulated and pathogenic. Currently, the best treatment for ROP is laser therapy, which does 
not significantly improve vision. Alternatively, glycoproteins are believed to play an important 
role in angiogenesis. Endomucin (EMCN), a glycoprotein, has been shown to be expressed by 
the venous and capillary endothelium. EMCN is believed to be associated with angiogenesis and 
could be a potential target for treatment of ROP. Thus, we hypothesize that EMCN is regulated 
by hypoxia and plays an important role in pathological angiogenesis.  
 Human retinal endothelial cells (HRECs), representative of endothelial cells involved in 
retinal angiogenesis, were deprived of oxygen using a hypoxia chamber. We established the 
optimal oxygen dosage, determined the optimal cell density, and monitored EMCN expression at 
different time points after exposure to hypoxia. Changes in gene expression in response to 
hypoxia were compared to control cells. Our preliminary data indicates that EMCN is regulated 
by hypoxia. Currently, we are investigating whether EMCN has similar effects in regulating 
revascularization in vivo. Taken together, our study indicates a novel role for EMCN during 
hypoxia-induced angiogenesis which may serve as a therapeutic target.  
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